Form 4: Mirum Pharmaceuticals CEO Christopher Peetz Reports Stock Transactions
SEC Form 4 Filing
Christopher Peetz, CEO of Mirum Pharmaceuticals, reports the acquisition and disposal of company stock, including the vesting of performance restricted stock units and sales to cover tax obligations.
Summary
- On March 15, 2025, Christopher Peetz, CEO of Mirum Pharmaceuticals, exercised performance restricted stock units, acquiring 50,000 shares of common stock.
- Following this transaction, Mr. Peetz directly owns 165,920 shares of Mirum Pharmaceuticals common stock.
- On March 17, 2025, Mr. Peetz sold 27,279 shares at a price of $44.2143 per share to cover tax withholding obligations related to the vesting of the restricted stock units, reducing his direct holdings to 138,641 shares.
- Mr. Peetz also indirectly owns 208,570 shares through The Peetz Family Trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies. It provides transparency into the transactions of company insiders and their holdings.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the sales are primarily for tax obligations and are not indicative of a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Exercise of performance restricted stock units resulting in the acquisition of 50,000 shares. |
| 03/17/2025 | Sale of 27,279 shares at $44.2143 per share to cover tax withholding obligations. |
| 03/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.